An antibody against RANKL for the treatment of osteoporosis, inflammatory and malignant bone diseases
- PMID: 20714812
- DOI: 10.1007/s10354-010-0812-3
An antibody against RANKL for the treatment of osteoporosis, inflammatory and malignant bone diseases
Abstract
Over the years, the importance of receptor activator of nuclear factor κB ligand (RANKL) in bone physiology and pathophysiology has been thoroughly documented. Denosumab, also known as AMG 162, is a fully human monoclonal antibody against RANKL which is being studied in the treatment of metabolic, inflammatory, and malignant bone diseases. The purpose of this review is to analyze the potential role of denosumab in osteoporosis, rheumatoid arthritis, bone metastases and multiple myeloma.
Similar articles
-
Denosumab.MAbs. 2009 May-Jun;1(3):210-5. doi: 10.4161/mabs.1.3.8592. Epub 2009 May 29. MAbs. 2009. PMID: 20065634 Free PMC article. Review.
-
RANK ligand inhibition with denosumab for the management of osteoporosis.Expert Opin Biol Ther. 2006 Oct;6(10):1041-50. doi: 10.1517/14712598.6.10.1041. Expert Opin Biol Ther. 2006. PMID: 16989586 Review.
-
Denosumab: an update.Drugs Today (Barc). 2011 Aug;47(8):605-13. doi: 10.1358/dot.2011.47.8.1603507. Drugs Today (Barc). 2011. PMID: 21850283 Review.
-
[Anti-RANKL monoclonal antibody Denosumab (AMG162)].Clin Calcium. 2011 Jan;21(1):46-51. Clin Calcium. 2011. PMID: 21187593 Review. Japanese.
-
Role of RANK ligand and denosumab, a targeted RANK ligand inhibitor, in bone health and osteoporosis: a review of preclinical and clinical data.Clin Ther. 2012 Mar;34(3):521-36. doi: 10.1016/j.clinthera.2012.02.002. Clin Ther. 2012. PMID: 22440513 Review.
Cited by
-
RANKL/RANK-beyond bones.J Mol Med (Berl). 2011 Jul;89(7):647-56. doi: 10.1007/s00109-011-0749-z. Epub 2011 Mar 29. J Mol Med (Berl). 2011. PMID: 21445556 Review.
-
Immunology of Osteoporosis: A Mini-Review.Gerontology. 2016;62(2):128-37. doi: 10.1159/000431091. Epub 2015 Jun 17. Gerontology. 2016. PMID: 26088283 Free PMC article. Review.
-
Pharmacological Management of Childhood-Onset Systemic Lupus Erythematosus.Paediatr Drugs. 2016 Jun;18(3):181-95. doi: 10.1007/s40272-016-0170-8. Paediatr Drugs. 2016. PMID: 26971103 Review.
-
[Osteoporosis in men receiving androgen deprivation therapy for non-metastatic prostate cancer].Wien Med Wochenschr. 2012 Sep;162(17-18):380-5. doi: 10.1007/s10354-012-0106-z. Epub 2012 Aug 9. Wien Med Wochenschr. 2012. PMID: 22875632 Review. German.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical